Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Conditions:   Head and Neck Squamous Cell Carcinoma;   Metastatic Squamous Cell Carcinoma
Interventions:   Radiation: SBRT;   Drug: Durvalumab + tremelimumab
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   AstraZeneca
Not yet recruiting - verified August 2017

http://ift.tt/2y8gBYE